심부정맥혈전증(DVT)의 전 세계 유병률은 좌식 생활습관, 비만, 고령, 흡연 및 당뇨병과 같은 위험요인의 존재 등의 요인으로 인해 증가하고 있습니다. 이러한 유병률 증가로 인해 효과적인 DVT 치료 옵션에 대한 수요가 증가하고 있습니다. 조기 진단과 신속한 치료는 합병증을 예방하고 환자의 예후를 최적화하기 위해 매우 중요하며, 이에 따라 DVT 치료 옵션에 대한 수요가 증가하여 2024년에는 11억 1,000만 달러, 2032년에는 약 14억 8,000만 달러에 달할 것으로 예상됩니다.
이와 더불어, DVT의 혁신적인 개선 치료법 개발에도 중점을 두고 있습니다. 기업들이 조사개발에 투자하여 효능, 안전성, 편의성을 개선한 신약, 의료기기, 치료법을 환자에게 제공함에 따라 2026-2032년 동안 연평균 3.96%의 성장률을 보일 것으로 예상됩니다.
심부정맥혈전증(DVT) 세계 시장 정의/개요
심부정맥혈전증(DVT)은 심부정맥에 혈전이 형성되는 것을 특징으로 하는 질환으로, 보통 다리에 혈전이 형성됩니다. 이 혈전은 혈류를 방해하여 생명을 위협하는 합병증인 폐색전증의 위험을 증가시킵니다.
DVT의 치료는 혈전이 커지거나 깨지는 것을 방지하고 합병증의 위험을 줄이는 데 중점을 둡니다. 치료법에는 항응고제, 혈전용해제, 기계적 혈전제거술 등이 있습니다.
지속적인 연구 개발로 DVT 치료는 발전하고 있습니다. 새로운 항응고제와 최소침습 수술이 개발되어 환자들에게 보다 효과적이고 편리한 치료법이 제공되고 있습니다. 또한, 조기 진단 및 예방 전략의 발전은 환자의 예후를 개선하고 DVT 발생률을 감소시키는 데 기여할 것으로 보입니다.
CDC의 보고에 따르면, 2023년 65세 이상 성인의 DVT 관련 입원이 28% 증가할 것으로 예상됩니다. 진단 도구, 특히 휴대용 초음파 장비의 기술 발전으로 조기 발견율이 향상되고 있습니다. 예를 들어, 2024년 2월 Medtronic은 AI를 활용한 새로운 DVT 위험 평가 플랫폼을 출시하여 조기 발견율을 40% 향상시켰다고 발표했으며, COVID 이후 환자들의 DVT 위험 요인에 대한 인식이 높아진 것도 발전에 기여하고 있습니다. COVID-19 환자의 31%가 DVT 합병증을 앓고 있다고 보고했습니다.
새로운 항응고 요법 및 기계적 예방 장치의 채택 확대는 전 세계 의료 지출 증가에 힘입어 시장 성장의 원동력이 되고 있습니다. 메디케어 및 메디케이드 서비스 센터에 따르면, DVT 예방 및 치료 비용은 2023년 123억 달러에 달할 것으로 예상되며, 연간 7.2%의 증가율을 보일 것으로 예측됩니다. 예를 들어, 2024년 3월 존슨앤드존슨의 자회사 에티콘은 자사의 새로운 기계식 압박 장치의 임상시험에서 수술 후 DVT 발병률을 45% 감소시켰다고 밝혔습니다. 최소침습 수술의 증가와 병원에서의 DVT 위험 평가 프로토콜의 의무화가 진행되면서 시장 확대가 더욱 가속화되고 있습니다.
높은 치료 비용과 제한적인 보험급여로 인해 DVT 시장은 큰 어려움을 겪고 있으며, Agency for Healthcare Research and Quality는 2023년 DVT 환자 1건당 평균 입원비용이 14,800달러에 달할 것으로 예상하고 있습니다. 이러한 경제적 부담은 첨단 치료법에 대한 보험 적용이 부족한 개발도상국에서 특히 심각합니다. 예를 들어, 2024년 3월 브리스톨 마이어스 스퀴브(Bristol-Myers Squibb)는 좋은 임상 결과에도 불구하고, 자사의 새로운 항응고제에 대한 보험 거부로 인해 22%의 환자들에게 영향을 미쳤다고 발표했습니다. 장기 항응고 요법에 대한 환자의 순응도에는 여전히 문제가 있으며, 치료 시작 후 6개월 이내 중단율은 30%에 달합니다.
DVT 시장은 다양한 의료 환경에서 진단 프로토콜과 치료 접근법을 표준화해야 하는 과제에 직면해 있으며, 세계보건기구(WHO)는 2023년 지역별로 DVT 관리 방법이 크게 다를 것으로 보고하고 있습니다. 적시에 개입하고 환자의 최적의 결과를 얻는 것이 지연되고 있습니다.
The global prevalence of deep vein thrombosis (DVT) is rising, driven by factors such as sedentary lifestyles, obesity, geriatric populations, and the presence of risk factors like smoking and diabetes. This increasing incidence has led to a growing demand for effective DVT treatment options. Early diagnosis and prompt treatment are crucial for preventing complications and optimizing patient outcomes, consequently driving the demand for DVT treatment options, surpassing USD 1.11 Billion valued in 2024 to reach a valuation of around USD 1.48 Billion by 2032.
In addition to this, ongoing efforts are focused on developing innovative and improved treatments for DVT. Companies are investing in research and development to introduce novel drugs, medical devices, and therapies that offer enhanced efficacy, safety, and convenience for patients, thus enabling the niche market grow at a CAGR of 3.96% from 2026 to 2032.
Global Deep Vein Thrombosis (DVT) Market: Definition/ Overview
Deep vein thrombosis (DVT) is a medical condition characterized by the formation of a blood clot in a deep vein, typically located in the legs. This clot can obstruct blood flow and increase the risk of pulmonary embolism, a potentially life-threatening complication.
The treatment of DVT focuses on preventing the clot from growing and breaking off, as well as reducing the risk of complications. Treatment options may include anticoagulant medications, thrombolytics, and mechanical thrombectomy.
Ongoing research and development efforts are driving advancements in DVT treatment. New anticoagulant medications and minimally invasive procedures are being developed to provide more effective and convenient options for patients. Additionally, advancements in early diagnosis and prevention strategies will contribute to improved patient outcomes and reduced incidence of DVT.
The rising prevalence of DVT, particularly among geriatric populations and post-surgical patients, is significantly expanding the market demand, with the CDC reporting a 28% increase in DVT-related hospitalizations among adults over 65 in 2023. Technological advancements in diagnostic tools, especially portable ultrasound devices, have improved early detection rates. For instance, in February 2024, Medtronic announced the launch of their new AI-powered DVT risk assessment platform, showing a 40% improvement in early detection rates. The growing awareness of DVT risk factors in post-COVID patients has also contributed to market growth, with the NIH reporting that 31% of severe COVID-19 patients developed DVT complications in 2023.
The expanding adoption of novel anticoagulant therapies and mechanical prophylaxis devices is driving market growth, supported by increasing healthcare expenditure globally. According to the Centers for Medicare & Medicaid Services, DVT prevention and treatment costs reached $12.3 billion in 2023, with a projected 7.2% annual increase. For instance, in March 2024, Johnson & Johnson's subsidiary Ethicon revealed that their new mechanical compression device achieved a 45% reduction in post-operative DVT incidents during clinical trials. The rise in minimally invasive surgical procedures and the increasing implementation of mandatory DVT risk assessment protocols in hospitals have further stimulated market expansion.
High treatment costs and limited reimbursement policies pose significant challenges in the DVT market, with the Agency for Healthcare Research and Quality reporting an average hospitalization cost of $14,800 per DVT case in 2023. The financial burden is particularly challenging in developing regions, where insurance coverage for advanced treatments remains inadequate. For instance, in March 2024, Bristol Myers Squibb announced that despite positive clinical outcomes, insurance denials for their novel anticoagulant therapy affected 22% of prescribed patients. Patient adherence to long-term anticoagulation therapy remains problematic, with discontinuation rates reaching 30% within the first six months of treatment.
The DVT market faces challenges in standardizing diagnostic protocols and treatment approaches across different healthcare settings, with the WHO reporting significant variations in DVT management practices across regions in 2023. Limited awareness among primary care physicians about early DVT symptoms and risk factors continues to delay timely interventions and optimal patient outcomes.
The anticoagulants segment maintains its market dominance due to its proven efficacy and expanding therapeutic options, with the FDA reporting a 28% increase in anticoagulant prescriptions for DVT treatment in 2023 compared to the previous year. Direct oral anticoagulants (DOACs) have revolutionized DVT management by offering convenient dosing regimens and reduced monitoring requirements. The development of reversal agents for anticoagulants has enhanced their safety profile, making them the preferred choice among healthcare providers and patients alike.
The market growth is further propelled by the introduction of biosimilars and generic alternatives, making treatment more accessible and cost-effective, with the U.S. Department of Health reporting a 31% reduction in average treatment costs for DVT patients using generic anticoagulants in 2023. Recent advancements in drug delivery systems and personalized dosing approaches have improved patient compliance and treatment outcomes. The expansion of indication ranges for existing anticoagulants and increased insurance coverage have significantly contributed to market penetration across different patient populations.
The surgical segment is dominating the global deep vein thrombosis (DVT) market, driven by the increasing adoption of minimally invasive thrombectomy procedures, with the FDA reporting a 28% year-over-year increase in approved surgical devices for DVT in 2023. The segment's growth is further propelled by technological advancements in surgical techniques and equipment, particularly in mechanical thrombectomy devices. The rising prevalence of post-operative DVT cases, especially in orthopedic and bariatric surgeries, has created a substantial demand for surgical interventions.
Advanced surgical techniques have shown superior outcomes in treating extensive DVT cases, with the American College of Surgeons reporting a 32% reduction in post-thrombotic syndrome when surgical interventions are used as primary treatment in 2023. The integration of robotic-assisted surgical systems and image-guided procedures has improved precision and reduced recovery times, making surgical options more appealing to both healthcare providers and patients.
How are the Advanced Healthcare Infrastructure and Market Players Maintaining the
North American Deep Vein Thrombosis (DVT) Dominance?
The North American DVT treatment market is maintaining its global dominance, largely driven by the United States, where according to the CDC's 2023 data, between 60,000-100,000 Americans die annually from DVT/PE (Pulmonary Embolism). This robust market position is further strengthened by the region's advanced healthcare infrastructure and the presence of key market players, exemplified by Janssen Pharmaceuticals' March 2024 announcement of expanding their XARELTO(R) (rivaroxaban) manufacturing facility in Puerto Rico to meet growing demand.
The market's leadership is also attributed to high disease awareness and extensive insurance coverage, with Medicare reporting in December 2023 that DVT treatments, including newer direct oral anticoagulants (DOACs), are covered under Part D for over 65 million beneficiaries. This regional dominance was further solidified when Bristol Myers Squibb announced in January 2024 their collaboration with major U.S. healthcare systems to implement AI-driven DVT risk assessment protocols, potentially revolutionizing early detection and treatment approaches.
The Asia Pacific region is experiencing significant growth in the global Deep Vein Thrombosis (DVT) treatment market. This growth is largely driven by rising incidences of DVT linked to sedentary lifestyles, obesity, and an geriatric population. Notably, government initiatives such as India's National Health Mission, which received about USD 5 million in funding for 2021-2022 to improve healthcare services, are enhancing access to DVT treatments.
Recent developments in the market further highlight this trend. For instance, in June 2021, the FDA approved Pradaxa (dabigatran etexilate) for pediatric patients aged 3 months to 12 years, marking a significant advancement in DVT treatment options. Additionally, major pharmaceutical companies like Pfizer and Bristol-Myers Squibb are increasing their investments in research and development, aiming to innovate and expand their product offerings in response to the growing demand for effective DVT therapies
The global deep vein thrombosis (DVT) market is a dynamic and competitive landscape, with a mix of established players and emerging challengers vying for market share. These players are actively working to strengthen their presence by implementing strategic plans such as collaborations, mergers, acquisitions, and political support. The organizations are dedicated to continuously improving their product line to meet the needs of a wide range of customers in different regions.
Some of the key players operating in the global deep vein thrombosis (DVT) market include:
Aspen Holdings
Novartis AG
Mylan N.V.
Momenta Pharmaceuticals, Inc.
Hikma Pharmaceuticals PLC
Laboratorios FarmaceuticosRovi, S.A.
GL Pharma
Cobapharma
BoehringerIngelheim GmbH
Glenmark Pharmaceuticals Inc.
In February 2024, for patients with deep vein thrombosis, Bayer initiated a Phase II clinical trial (SIRIUS study) for BAY3018250, a first-in-class anti-alpha2 antiplasmin (anti-a2ap) antibody. The plasmin inhibitor a2ap, which is essential for blood coagulation and breaks up clots in situ, is inhibited by BAY3018250.
In November 2023, during a Late-Breaking session of the American Heart Association (AHA) meeting, Anthos Therapeutics, Inc. reported a highly significant reduction in bleeding events across all primary and secondary endpoints by abelacimab when compared to a standard-of-care direct-oral anticoagulant (DOAC)
In June 2021, Pradaxa (dabigatran etexilate), the first oral blood thinner approved by the FDA, is used to treat DVT in children aged three months to twelve years.